Older adults have the highest incidence of traumatic brain injury globally. Accurate blood-
based biomarkers are needed to assist with diagnosis of patients across the spectrum of age …

Blood levels of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase-
L1 (UCH-L1) within 12h of suspected traumatic brain injury (TBI) have been approved by the …

Objective: Identification and validation of blood-based biomarkers for the diagnosis and
prognosis of mild traumatic brain injury (mTBI) is of critical importance. There have been …

Objective The objective was to determine the accuracy of a new, rapid blood test combining
measurements of both glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl‐terminal …

Background Several studies have reported an association between serum biomarker values
and functional outcome following traumatic brain injury. We aimed to examine the …

Introduction A blood-based biomarker (BBBM) test could help to better stratify patients with
traumatic brain injury (TBI), reduce unnecessary imaging, to detect and treat secondary …

Blood-based biomarkers have been increasingly studied for diagnostic and prognostic
purposes in patients with mild traumatic brain injury (MTBI). Biomarker levels in blood have …

Objective The objective was to compare test characteristics of a single serum concentration
of glial fibrillary acidic protein (GFAP), S‐100β, and ubiquitin carboxyl terminal hydrolase L1 …

Glial fibrillary acidic protein (GFAP) is cleared by the Food and Drug Administration (FDA) to
determine need for head computed tomography (CT) within 12 h after mild traumatic brain …

Abstract Purpose of Review This review seeks to explore blood-based biomarkers with the
potential for clinical implementation. Recent Findings Emerging non-proteomic biomarkers …